Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
Brent A. Neuschwander-Tetri, Elizabeth M. Brunt, Kent R. Wehmeier, Dana Oliver, Bruce R. BaconVolume:
38
Year:
2003
Language:
english
Pages:
10
DOI:
10.1002/hep.1840380427
File:
PDF, 963 KB
english, 2003